Biomarker ID | 561 |
PMID | 21060327 |
Year | 2010 |
Biomarker | C8orf4; TMC5; PDLIM5; JAG1; HOXA9; C4A; STEAP4; HLA-DMB; COL12A1; DHRS8; C10orf137; SLC7A1; PDZRN3; F3; ACER3; POLB; PXDN; PROM2; GUCY1A3; SOX4; |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated (Fold Change): [C8orf4 (5.14 fold); TMC5 (4.83 fold) ; PDLIM5 (4.51 fold); JAG1 (4.36 fold); HOXA9 (4.25 fold) ; C4A (3.98 fold); STEAP4 (3.92 fold); HLA-DMB (3.85fold); COL12A1 (3.81 fold); DHRS8 (3.81 fold); C10orf137 (3.62 fold); SLC7A1 (3.44 fold); PDZRN3 (3.30 fold); F3 (3.26 fold) ; ACER3 (3.17fold); POLB (3.16 fold); PXDN (3.12 fold); PROM2 (3.11 fold); GUCY1A3 (3.10 fold); SOX4 (3.02 fold);] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(HOAX9):-Oncostatin M, Pathways Include(JAG1):- Activated NOTCH1 signaling in the nucleus,Proteins and DNA sequences in cardicac structureS,Initiation of the second proteolytic cleavage of Notch receptor by receptor-ligand binding,Gastrin pathway,TAp63 pathway |
Experiment | High BMI Tumor Vs High BMI Normal |
Type of Biomarker | Diagnostic |
Cohort | 6 patients with Normal BMI and 6 patients with High BMI were chosen for the study. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | qRT-PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | C8orf4, TMC5, PDLIM5, JAG1, HOXA9, C4A, STEAP4, HLA-DMB, COL12A1, DHRS8, C10orf137, SLC7A1, PDZRN3, F3, ACER3, POLB, PXDN, PROM2, GUCY1A3, SOX4 |